BBA
SKYE icon

Baker Bros. Advisors’s Skye Bioscience SKYE Stock Holding History

Baker Bros. Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Hold
196,905
– – 0.01% 80
2026
Q1 		$968K Buy
196,905
+15,575
+9% +$102K 0.01% 80
2025
Q4 		$1.09M Hold
181,330
– – 0.01% 81
2025
Q3 		$5.7M Hold
181,330
– – 0.04% 71
2025
Q2 		$6.06M Hold
181,330
– – 0.06% 63
2025
Q1 		$2.31M Hold
181,330
– – 0.03% 72
2024
Q4 		$4.11M Buy
181,330
+2,001
+1% +$66.9K 0.04% 74
2024
Q3 		$5.61M Buy
179,329
+116,829
+187% +$5.24M 0.06% 64
2024
Q2 		$4M Buy
+62,500
New +$5.93M 0.05% 72

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baker Bros. Advisors's SKYE Position: Q2 2026 in Review

Baker Bros. Advisors held its Skye Bioscience (SKYE) position steady in Q2 2026 at 196,905 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #80.

Baker Bros. Advisors first reported a position in SKYE in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.06M in Q2 2025. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Baker Bros. Advisors held 196,905 shares of Skye Bioscience worth $1.09M as of Q2 2026.
  • Baker Bros. Advisors left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up 0.01% of Baker Bros. Advisors's portfolio in Q2 2026, its #80 holding.
  • Baker Bros. Advisors first reported a position in Skye Bioscience in Q2 2024 and has held it in 9 quarters since.
  • Baker Bros. Advisors's Skye Bioscience position peaked at $6.06M in Q2 2025.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.